Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 6
1993 50
1994 67
1995 81
1996 104
1997 129
1998 116
1999 116
2000 100
2001 87
2002 99
2003 125
2004 83
2005 112
2006 111
2007 98
2008 94
2009 120
2010 115
2011 114
2012 113
2013 125
2014 123
2015 152
2016 138
2017 147
2018 155
2019 155
2020 111
2021 24
Text availability
Article attribute
Article type
Publication date

Search Results

2,874 results
Results by year
Filters applied: . Clear all
Page 1
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. Dale DC, et al. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Support Care Cancer. 2018. PMID: 28939926 Free PMC article. Review.
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. ...CONCLUSIONS: This systematic literature review and meta-analysis …
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing …
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Smith TJ, et al. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169616 Review.
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routin …
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the rec …
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L, Baser O, Kutikova L, Page JH, Barron R. Wang L, et al. Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29. Support Care Cancer. 2015. PMID: 25821144 Free PMC article. Review.
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerical but statistically nonsignificant increase in the FN risk for lipegfilgrastim PP versus pegfilgrastim PP. Using MTC in cycle 1, PP with …
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerica …
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Bond TC, et al. J Oncol Pharm Pract. 2018 Sep;24(6):412-423. doi: 10.1177/1078155217714859. Epub 2017 Jun 14. J Oncol Pharm Pract. 2018. PMID: 28614980 Free PMC article. Review.
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgrastim. Methods Embase was searched for trials examining the efficacy/safety of lipegfilgrastim, pegfilgrastim, or filgrastim. ...Dire …
The current meta-analysis compared the neutropenia-related efficacy and safety of lipegfilgrastim to those of pegfilgrastim and filgrasti
Science of Biosimilars.
Harvey RD. Harvey RD. J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. J Oncol Pract. 2017. PMID: 28898589 Review.
Postmarketing surveillance programs will be required to evolve and ensure optimal pharmacovigilance reporting, because the potential for unexpected adverse events with biosimilars is higher than with conventional generic agents as a result of different manufacturing processes and …
Postmarketing surveillance programs will be required to evolve and ensure optimal pharmacovigilance reporting, because the potential for une …
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Aapro M, et al. Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Support Care Cancer. 2017. PMID: 28842778 Free PMC article. Review.
Current guidelines provide recommendations on granulocyte colony-stimulating factors (G-CSF) for prevention of FN, but guidance is unclear regarding use of short- vs long-acting G-CSF (e.g., filgrastim vs pegfilgrastim/lipegfilgrastim, respectively). An international panel …
Current guidelines provide recommendations on granulocyte colony-stimulating factors (G-CSF) for prevention of FN, but guidance is unclear r …
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N. Blackwell K, et al. Ann Oncol. 2015 Sep;26(9):1948-1953. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28. Ann Oncol. 2015. PMID: 26122726 Free PMC article. Clinical Trial.
BACKGROUND: Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen(), in breast cancer patients receiving (neo)adjuvant myelosuppressive chemo …
BACKGROUND: Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrasti
2,874 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page